市場調査レポート
商品コード
1451029
セルベースアッセイ市場レポート:製品・サービス、技術、用途、エンドユーザー、地域別、2024-2032Cell-based Assay Market Report by Product and Services, Technology, Application, End-User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
セルベースアッセイ市場レポート:製品・サービス、技術、用途、エンドユーザー、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2~3営業日
|
世界のセルベースアッセイ市場規模は2023年に225億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて7.2%の成長率(CAGR)を示し、2032年までに429億米ドルに達すると予測しています。さまざまな疾患に対処するための新規治療に対する需要の高まり、個別化医療への注目の高まり、薬剤スクリーニングの精度を向上させるための細胞培養技術の革新などが、市場を推進する主な要因の一部です。
セルベースアッセイは、特定の物質や条件に反応する細胞の生物学的活性を評価するために、様々な科学・医療分野で使用される実験技術です。制御された環境で生きた細胞を培養し、薬物、化合物、環境因子などの様々な刺激にさらすことからなります。細胞の生存率や特定のバイオマーカーの発現など、細胞の挙動における変化をモニターすることで、研究者は試験物質が細胞機能に及ぼす影響について重要な洞察を得ることができるため、細胞ベースのアッセイに対する需要は世界的に高まっています。
現在、創薬、毒性学研究、疾患モデリング、細胞メカニズムの解明などのためにセルベースアッセイの採用が増加しており、市場の成長を支えています。これに加えて、医薬化合物の潜在的な有効性と安全性を評価するニーズの高まりが、市場の成長を強化しています。さらに、研究者が市場開拓の初期段階で潜在的な副作用を特定し、化学物質の毒性を評価することを可能にする細胞ベースのアッセイに対する需要の高まりは、市場にプラスの影響を与えています。これとは別に、がん、糖尿病、自己免疫疾患などの慢性疾患が世界中で増加していることも、業界の投資家に有利な成長機会をもたらしています。さらに、化学物質や汚染物質が植物や水生システムに与える影響を評価する必要性の高まりが、市場の成長を後押ししています。
様々な疾患に対処するための新規治療に対する需要の高まり
創薬・薬剤開発への注目の高まりに加え、世界中の人々の間で様々な慢性疾患に対処するための新規療法への需要が高まっていることが、市場の成長に寄与しています。加えて、細胞ベースのアッセイは、研究者が膨大な数の潜在的な薬剤候補を迅速かつ効率的にスクリーニングし、評価することを可能にします。細胞をさまざまな化合物に暴露することで、科学者はその有効性や安全性プロファイルなど、細胞の挙動への影響を評価することができます。これとは別に、薬剤が特定の細胞経路とどのように相互作用するかを深く理解する必要がある精密医療への注目が高まっています。さらに、これらのアッセイは、個々の患者のプロファイルに合わせて薬物治療を調整するためのプラットフォームを提供します。
個別化医療への注目の高まり
大衆の間で個別化医薬品への注目が高まっていることが、市場の成長を支えています。これに伴い、ヘルスケア施設は、個々の患者の遺伝的、分子的、細胞的特徴に合わせてカスタマイズされた治療ソリューションに急速に注目しています。これに加えて、細胞ベースのアッセイによって、研究者は様々な薬剤や治療に対する患者由来の細胞の反応を評価することができ、潜在的な副作用を最小限に抑えながら、最も効果的な治療法を特定することが可能になります。さらに、個別化医療は治療成績を向上させるだけでなく、効果のない治療を避けることでヘルスケアコストを削減します。その結果、臨床と研究の両方の場面で細胞ベースのアッセイの採用が増加しています。細胞ベースのアッセイは、医療介入を患者の特定のニーズに合わせて調整するための強力なツールとなるからです。
細胞培養技術の革新
細胞培養技術の進歩は、細胞ベースのアッセイの能力を高めています。3D培養やオルガノイドにより、研究者はより人体に近い細胞挙動を研究し、薬剤スクリーニングや毒性試験の精度を向上させることができます。さらに、マイクロフルイディクスとラボオンチップ技術により、小型化・自動化されたセルベースアッセイの開発が可能になり、創薬のスループットと効率性の向上に寄与しています。これに伴い、これらの先進的な細胞培養技術を細胞ベースのアッセイに統合することで、その関連性と適用性を高めることができ、疾患メカニズムの解明や、より精度の高い医薬品候補の評価に適したツールとなります。
The global cell-based assay market size reached US$ 22.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 42.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032. The growing demand for novel therapies to address various diseases, rising focus on personalized medicines, and innovations in cell culture technologies to improve the accuracy of drug screening are some of the major factors propelling the market.
A cell-based assay, also known as a cellular assay, is a laboratory technique that is used in various scientific and medical fields to assess the biological activity of cells in response to specific substances or conditions. It comprises culturing living cells in controlled environments and exposing them to various stimuli, such as drugs, compounds, or environmental factors. As it allows researchers to gain critical insights into the effects of the tested substances on cellular function by monitoring changes in cell behavior, such as cell viability or the expression of specific biomarkers, the demand for cell-based assay is increasing worldwide.
At present, the rising adoption of cell-based assays for drug discovery, toxicology studies, disease modeling, and understanding cellular mechanisms is supporting the growth of the market. Besides this, the increasing need to evaluate the potential efficacy and safety of pharmaceutical compounds is strengthening the growth of the market. Additionally, the growing demand for cell-based assays, as they enable researchers to identify potential adverse effects early in the development process and assess the toxicity of chemicals, is positively influencing the market. Apart from this, increasing incidences of numerous chronic diseases, such as cancer, diabetes, and autoimmune disorders, among individuals around the world are offering lucrative growth opportunities to industry investors. Furthermore, the rising need to assess the impact of chemicals and pollutants on plant and aquatic systems is bolstering the growth of the market.
Rising demand for novel therapies to address various diseases
The rising focus on drug discovery and development, along with the increasing demand for novel therapies to address various chronic diseases among individuals across the globe, is contributing to the growth of the market. In addition, cell-based assays enable researchers to screen and evaluate a vast number of potential drug candidates quickly and efficiently. By exposing cells to different compounds, scientists can assess their impact on cellular behavior, including their efficacy and safety profiles. Apart from this, there is an increase in the focus on precision medicine that necessitates a deep understanding of how drugs interact with specific cellular pathways. Moreover, these assays provide a platform for tailoring drug treatments to individual patient profiles.
Increasing focus on personalized medicines
The rising focus on personalized medicines among the masses is supporting the growth of the market. In line with this, healthcare facilities are rapidly focusing on treatment solutions that are customized to suit the genetic, molecular, and cellular characteristics of individual patients. Besides this, cell-based assays allow researchers to evaluate the response of patient-derived cells to various drugs and treatments and enable the identification of the most effective therapies while minimizing potential side effects. In addition, personalized medicine not only improves treatment outcomes but also reduces healthcare costs by avoiding ineffective treatments. As a result, there is an increase in the adoption of cell-based assays in both clinical and research settings, as they provide a powerful tool for tailoring medical interventions to the specific needs of patients.
Innovations in cell culture technologies
Advancements in cell culture techniques are enhancing the capabilities of cell-based assays. 3D cultures and organoids allow researchers to study cell behavior closer to the human body to improve the accuracy of drug screening and toxicity testing, which is offering a positive market outlook. Additionally, microfluidics and lab-on-a-chip technologies enable the development of miniaturized and automated cell-based assays that assist in increasing throughput and efficiency in drug discovery. In line with this, the integration of these advanced cell culture technologies into cell-based assays aids in enhancing their relevance and applicability, which makes them suitable tools for understanding disease mechanisms and evaluating drug candidates with greater precision.
IMARC Group provides an analysis of the key trends in each segment of the global cell-based assay market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on product and services, technology, application and end-user.
Consumables
Reagents and Media
Cells and Cell Lines
Probes and Labels
Instruments
Microplates
Microplate Readers
High Throughput Screening
Liquid Handling Systems
Services
Software
Consumables represent the largest market segment
The report has provided a detailed breakup and analysis of the market based on the product and services. This includes consumables (reagents and media, cells and cell lines, and probes and labels), instruments (microplates, microplate readers, high throughput screening, and liquid handling systems), services, and software. According to the report, consumables represented the largest segment. Consumables refer to a wide range of disposable laboratory materials and reagents that are essential for conducting cell-based experiments and assays. They include cell culture media, reagents for cell proliferation and viability assays, cell culture plates, assay kits, antibodies, and other materials used on a one-time or limited-use basis. In addition, consumables ensure the proper growth and maintenance of cells in culture and provide the necessary tools for detecting cellular responses that enable the execution of various assays efficiently. They play a crucial role in ensuring the accuracy, reproducibility, and reliability of results in cell-based experiments.
Automated Handling
Flow Cytometry
Label-Free Detection
High-Throughput Screening
Others
High-throughput screening accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the technology. This includes automated handling, flow cytometry, label-free detection, high-throughput screening, and others. According to the report, high-throughput screening represented the largest segment. High-throughput screening (HTS) is a technology-driven approach used in drug discovery, which allows researchers to quickly test thousands to millions of compounds for their biological activity. HTS systems are designed to automate the screening process and enable the rapid evaluation of potential drug candidates. It involves the use of robotic systems and specialized equipment to perform assays on a large scale. It typically utilizes microplates with multiple wells, where each well contains cells or biochemical components for testing. The technology allows for the identification of compounds that exhibit desired biological effects, such as binding to a specific target or modulating a cellular response.
Drug Discovery
Basic Research
ADME Studies
Predictive Toxicology
Others
Drug discovery dominates the market share
The report has provided a detailed breakup and analysis of the market based on the application. This includes drug discovery, basic research, ADME studies, predictive toxicology, and others. According to the report, drug discovery represented the largest segment. Drug discovery refers to the techniques and technologies used to administer therapeutic substances, such as drugs or biologics, to the targeted cells or tissues within the body. These assays play a critical role in the development and optimization of drug delivery systems by providing valuable insights into their efficacy and safety. In addition, they are used to assess targeted delivery, screen for cellular uptake, evaluate drug release kinetics, and assay drug toxicity. Researchers employ cell-based models to evaluate the ability of drug delivery systems, such as nanoparticles or liposomes, to specifically target and interact with particular cell types or tissues.
Pharmaceutical and Biotechnology Companies
Academic and Government Institutions
Contract Research Organizations
Others
Pharmaceutical and biotechnology companies hold the biggest market share
The report has provided a detailed breakup and analysis of the market based on the end-user. This includes pharmaceutical and biotechnology companies, academic and government institutions, contract research organizations, and others. According to the report, pharmaceutical and biotechnology companies represented the largest segment. Pharmaceutical and biotechnology employ these assays to identify and validate potential drug candidates, assess their efficacy, and evaluate safety profiles. They enable high-throughput screening of compound libraries that enhance the drug development pipeline. In line with this, these companies utilize these assays to ensure the safety of drug candidates. These assays assist in assessing the cytotoxicity and potential adverse effects of compounds that benefit companies complying with regulatory requirements. Moreover, these assays are employed for quality control purposes to ensure the consistency and reliability of pharmaceutical and biotechnological products.
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
North America exhibits a clear dominance, accounting for the largest cell-based assay market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the increasing demand for advanced assay technologies and consumables. In addition, the rising development of novel cell-based assay techniques is bolstering the growth of the market in the region. Apart from this, the growing focus on drug safety is positively influencing the market. In line with this, stringent regulatory standards are propelling the growth of the market in the North America region.
Major players are developing innovative assay technologies, such as novel reagents, assay kits, and platforms. This involves creating more physiologically relevant cell models to improve assay sensitivity and enhance automation and data analysis capabilities. In line with this, companies are expanding their product portfolios to cater to a wide range of applications. This includes offering assays tailored for specific targets, pathways, or disease models, and developing specialized kits for toxicity testing and drug screening. Apart from this, key manufacturers are providing customized assay development services and are working closely with clients to tailor assays to their specific research needs, which is offering a positive market outlook.
Becton, Dickinson and Company
Global Life Sciences Solutions USA LLC (DBA Cytiva)
Thermo Fisher Scientific Inc.
Merck Group
PerkinElmer Inc.
Charles River Laboratories Inc.
Lonza Group Ltd.
Cell Signaling Technology
Promega Corporation
Cell Biolabs Inc.
Eurofins DiscoverX Corporation
Bio-Rad Laboratories Inc.
Corning Inc.
F. Hoffmann-La Roche AG (Roche Holding AG)
In December 2021, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of PPD, Inc. to provide a complete suite of services across the clinical development spectrum, comprising scientific discovery, safety, efficacy and healthcare outcome assessment, handling trial logistics, and the development and production of the therapeutics.
In March 2022, Promega Corporation and FUJIFILM Cellular Dynamics, Inc. announced a strategic collaboration to advance novel assay development for drug discovery. The collaboration will merge bioluminescent reporter technology used to study cellular signaling and transcriptional activity in iPSCs.
In 2022, BD (Becton, Dickinson and Company) introduced the BD Rhapsody(TM) TCR/BCR Multiomic Assay, an innovative set of reagents that enables researchers to more easily and comprehensively analyze important cells in the immune system and provide a tool to advance research in autoimmune disorders, immuno-oncology and infectious diseases.